Combination therapy combats aggressive breast cancer
نویسندگان
چکیده
منابع مشابه
Electro-endocrine combination therapy for aggressive breast tumors
Obesity is an epidemic in the US and an established risk factor for breast cancer incidence and morbidity. In obese patients breast cancer is commonly more aggressive and associated with poor prognosis. The goal of our research is to develop safe and efficient novel therapies to treat aggressive breast tumors, like those in obese patients. To enhance drug uptake we intend to develop electro-end...
متن کاملCombination endocrine therapy in the management of breast cancer.
Combination endocrine therapy has long been sought after as a means to better treat breast cancer. Agents that suppress estrogen production are given with agents that suppress estrogenic activity at the cellular level. Historically, these combinations have resulted in initial improvements in response rates, but relapse-free and overall survival were not significantly improved. Also, the increas...
متن کاملCapecitabine-based combination therapy for breast cancer: implications for nurses.
PURPOSE/OBJECTIVES To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer. DATA SOURCES Peer-reviewed publications or abstracts from major oncology conferences and reviews of capecitabine focusing on nursing implications. DATA SYNTHESIS Capecitabine has proven efficacy in combination with docetaxel and is under evalu...
متن کاملCarboplatin in combination therapy for metastatic breast cancer.
BACKGROUND Anthracycline-based regimens have a limited role in patients with metastatic breast cancer due to cumulative cardiotoxicity and their common use in adjuvant chemotherapy. New nonanthracycline regimens are, therefore, needed for metastatic disease. Single-agent carboplatin is active in patients with previously untreated metastatic breast cancer, producing response rates of 20%-35%. Pr...
متن کاملPrecision medicine and personalized breast cancer: combination pertuzumab therapy
Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the formation of HER2:HER3 dimers, which is the most potent heterodimer in the HER family. The combination...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Drug Discovery
سال: 2020
ISSN: 1474-1776,1474-1784
DOI: 10.1038/d41573-020-00065-5